Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

BACKGROUND: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). METHODS: We investigated whether expression ratios of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Hematol Oncol
Prif Awduron: Niewerth, Denise, Kaspers, Gertjan J. L., Jansen, Gerrit, van Meerloo, Johan, Zweegman, Sonja, Jenkins, Gaye, Whitlock, James A., Hunger, Stephen P., Lu, Xiaomin, Alonzo, Todd A., van de Ven, Peter M., Horton, Terzah M., Cloos, Jacqueline
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2016
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5011854/
https://ncbi.nlm.nih.gov/pubmed/27599459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0312-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg